Cargando…

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAF(V600E)

Detalles Bibliográficos
Autores principales:	Milne, Paul, Abhyankar, Harshal, Scull, Brooks, Singh, Preeti, Chakraborty, Rikhia, Allen, Carl E., Collin, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631653/ https://www.ncbi.nlm.nih.gov/pubmed/35816634 http://dx.doi.org/10.1182/bloodadvances.2022007519

Ejemplares similares

Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022)

New somatic BRAF splicing mutation in Langerhans cell histiocytosis
por: Héritier, Sébastien, et al.
Publicado: (2017)

BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020)

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016)

BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
por: Bates, Sara V., et al.
Publicado: (2013)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review
por: Wake, Laura, et al.
Publicado: (2019)

Synchronous and Metachronous Thyroid Cancer in Relation to Langerhans Cell Histiocytosis; Involvement of V600E BRAF-Mutation?
por: Moschovi, Maria, et al.
Publicado: (2015)

Clinicopathological features and BRAF(V600E) mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis
por: Huo, Zhen, et al.
Publicado: (2016)

Association between clinicopathologic characteristics and BRAF(V600E) expression in Chinese patients with Langerhans cell histiocytosis
por: Huang, Hui, et al.
Publicado: (2019)

A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children
por: Phan, Thu Dang Anh, et al.
Publicado: (2021)

Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis
por: Cui, Lei, et al.
Publicado: (2020)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis
por: Nelson, David S., et al.
Publicado: (2019)

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF(V600E)-Mutated Langerhans Cell Histiocytosis
por: Yang, Ying, et al.
Publicado: (2021)

BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis
por: Kudo, Ko, et al.
Publicado: (2022)

Adult Onset of BRAF(V600E)-Mutated Langerhans Cell Histiocytosis with Cutaneous Involvement Successfully Diagnosed by Immunohistochemical Staining
por: Tono, Hisayuki, et al.
Publicado: (2015)

Genetic homogeneity of adult Langerhans cell histiocytosis lesions: Insights from BRAF(V600E) mutations in adult populations
por: Selway, Joanne Louise, et al.
Publicado: (2017)

Multisystemic Pediatric Langerhans cell histiocytosis: a comprehensive clinico-pathological and BRAF V600E mutation study at autopsy
por: Kapatia, Gargi, et al.
Publicado: (2020)

BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis
por: Zeng, Kaixuan, et al.
Publicado: (2016)

Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing
por: Feng, Shunqiao, et al.
Publicado: (2021)

Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis
por: Pan, Yaozhu, et al.
Publicado: (2019)

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
por: Berres, Marie-Luise, et al.
Publicado: (2014)

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
por: Berres, Marie-Luise, et al.
Publicado: (2015)

Langerhans cell histiocytosis
por: Aruna, D. R., et al.
Publicado: (2011)

Langerhans cell histiocytosis
por: Kumar, Manish, et al.
Publicado: (2018)

BRAF Mutation Analysis in Two Cases of Congenital Self-Healing Langerhans Cell Histiocytosis
por: Takayama, Saki, et al.
Publicado: (2022)

Three decades of progress from surgery to medical therapy for isolated neuroaxis BRAF V600E–positive Langerhans cell histiocytosis management: illustrative case
por: Muthiah, Nallammai, et al.
Publicado: (2021)

Impact of BRAF(V600E) mutation on aggressiveness and outcomes in adult clonal histiocytosis
por: Razanamahery, Jerome, et al.
Publicado: (2023)

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
por: Tóth, Béla, et al.
Publicado: (2020)

Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
por: Holst, Johanne Marie, et al.
Publicado: (2021)

BRAF- and MAP2K1-Negative Multisystem Langerhans Cell Histiocytosis in an Elderly Patient
por: Kothari, Rohit, et al.
Publicado: (2023)

Langerhans cell histiocytosis of the sternum
por: Tsuchie, Hiroyuki, et al.
Publicado: (2009)

Pulmonary langerhans cell histiocytosis
por: Suri, Harpreet S, et al.
Publicado: (2012)

Langerhans cell histiocytosis of the sacrum
por: Hatem, M.A.
Publicado: (2015)

Langerhans cell histiocytosis of the bone
por: Huang, Wen-Chih, et al.
Publicado: (2017)

Langerhans Cell Histiocytosis of the Tonsil
por: Cipolla, Federica, et al.
Publicado: (2022)

Langerhans Cell Histiocytosis of the Mandible
por: Padmanaban, Kamalakannan, et al.
Publicado: (2022)

Optimal Therapy for Adults with Langerhans Cell Histiocytosis Bone Lesions
por: Cantu, Maria A., et al.
Publicado: (2012)

Apparent Lack of BRAF(V600E) Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8(+) T Cells in Langerhans Cell Histiocytosis
por: Kemps, Paul G., et al.
Publicado: (2020)

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children
por: Wang, Leyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_earq18jp3o982fgab4q82cfblp